The present disclosure relates to 1,3-diphenylpropane derivatives of formula (I), pharmaceutical compositions comprising the same and therapeutic uses thereof, in particular in the fields of human and animal health. The compounds according to the present disclosure have intrinsic PPAR agonist properties. They are therefore of particular interest in the treatment of metabolic and/or inflammatory diseases and particularly peripheral and central diseases associated with the metabolic syndrome, such as diverse forms of steatohepatitis, type 2 diabetes, diverse neurodegenerative disorders,such as Alzheimer&rsquosdisease, Parkinson&rsquos disease and multiple sclerosis.
